<DOC>
	<DOCNO>NCT03071042</DOCNO>
	<brief_summary>This study evaluate tolerance , safety efficacy Apatinib plus Docetaxel second-line treatment locally advance metastatic gastric cancer ( include Gastroesophageal junction ( GEJ ) Adenocarcinoma ) .</brief_summary>
	<brief_title>A Clinical Trial Apatinib Plus Docetaxel Locally Advanced Metastatic Gastric GEJ Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Patient voluntarily join study sign Informed Consent Form study ; 2 . Age : ≥18 year old ; 3 . Locally advanced metastatic gastric cancer ( include Gastroesophageal junction ( GEJ ) Adenocarcinoma ) patient confirm radiologic imaging endoscopy test , fail firstline treatment ; Firstline treatment 5Fu combine platinum base regimen ; Adjuvant/neoadjuvant chemotherapy define firstline treatment , recurrence happen within 6 month completion 5Fu platinum base adjuvant/ neoadjuvant chemotherapy ; 4 . Adjuvant/neoadjuvant chemotherapy history allow , firstline treatment apply 6 month later prior treatment ; 5 . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure ; 6 . ECOG Performance Status ≤1 ; 7 . Life expectancy n't less 16 week , since first medicine application time ; 8 . Major organ function meet follow criterion ( within 28 day treatment ) : HB ≥9.0 g/dL ANC ≥1.5X109/L PLT ≥100x109/L Bilirubin ≤1.5 time upper limit normal ( ULN ) ALT ( SGOT ) AST ( SGPT ) ≤2.5 × ULN , unless liver metastasis ; , ALT AST≤5 × ULN Serum Cr ≤ 1.5 x ULN 9 . Patients must least one assessable lesion ( include measurable and/or immeasurable ) radiological imagine ( CT/MRI ) ; 10 . Pregnancy test ( serum urine ) perform woman childbearing age within 28 day enrollment test result must negative . Or menopause woman , define follow : ≥1 year menstruation , abort exogenous hormone treatment Serum LH FSH meet menopause criterion More 1 year menstruation ovarian function failure induce radiation therapy . More 1 year menstruation menopause induce chemotherapy Surgical sterilization accept ( hysterectomy ovariectomy ) 1 . Involved another ongoing clinical trial ; 2 . Accept one chemotherapy previously advance gastric cancer ( except 6 month adjuvant/neoadjuvant treatment ) ; 3 . Prior taxane treatment ( include Paclitaxel Docetaxel ) ; 4 . Prior VEGFR inhibitor treatment ( include Sorafenib Sunitinib ) ; 5 . History another malignancy within last five year except cured nonmelanoma Skin cancer carcinoma situ uterine cervix ; 6 . Any factor influence usage oral administration ; 7 . History investigational agent treatment 14 day prior enroll study ( long time period may require depends drug characteristic ) ; 8 . Accept chemotherapy radiotherapy ( exclude Palliative radiotherapy ) 3 week prior study ( long time period may require depends drug characteristic ) ; 9 . Poorcontrolled arterial hypertension ( systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mm Hg ) despite standard medical management ; Coronary heart disease great Class I ; Ilevel arrhythmia ( include QT interval prolongation , man ≥ 450 m , woman ≥ 470 m ) together Class I cardiac dysfunction ; Patients positive urinary protein ; 10 . Poorcontrolled adverse event ( exclude Alopecia ) induce tumor therapy ( &gt; class 1 CTCAE ) ; 11 . History intestinal obstruction class 3 4 ( CTCAE ) gastrointestinal bleed 4 week prior enroll study ; 12 . Abnormal Coagulation ( INR &gt; 1.5、APTT &gt; 1.5 UNL ) , tendency bleed ; 13 . Clinical evidence central nervous system ( CNS ) poorcontrolled CNS metastasis ( No necessary confirm negative CNS metastasis CT/MRI ) ; 14 . Surgery within 2 week prior enroll study ; 15 . History significant poorcontrolled disease infection , opinion investigator , may impact safety patient study ; 16 . Known history human immunodeficiency , e.g . HIV positive ; 17 . Known suspected allergy investigational agent agent give association trial ; 18 . Pregnant lactating patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>